Abatacept in spondylarthritis refractory to tumour necrosis factor α inhibition

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 151-152

  Olivieri, I ^a   D'Angelo, S ^a   Mennillo, G A ^a   Pistone, G ^b   Scarano, E ^a   Padula, A ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Rheumatology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ACHILLES TENDON; BUTTOCK PAIN; CASE REPORT; DRUG DOSE REDUCTION; EDEMA; ENTHESITIS; EVOLUTION; FEMALE; HUMAN; INFORMED CONSENT; INTERPHALANGEAL JOINT; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PELVIS RADIOGRAPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SACROILIAC JOINT; SACROILIITIS; SACRUM; SPONDYLITIS; STERNOCLAVICULAR JOINT; TREATMENT RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; SPONDYLARTHRITIS;

FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58349097894     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097030     Document Type: Letter

References (5)

1. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase lIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:2263-71.
2. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistam active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
3. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58:953-63.
4. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4lg-mediated blockage of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-52.
5. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4lg) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681-94.